

# 1 Incretin hypersecretion in gestational 2 diabetes mellitus

## 3 4 Short running title: Incretins in GDM

5  
6 Louise Fritsche<sup>1,2</sup>, Martin Heni<sup>1,2,3,4</sup>, Sabine S. Eckstein<sup>1,2</sup>, Julia Hummel<sup>1,2</sup>, Anette  
7 Schürmann<sup>2,5</sup>, Hans-Ulrich Häring<sup>1,2,3</sup>, Hubert Preißl<sup>1,2</sup>, Andreas L. Birkenfeld<sup>1,2,3</sup>,  
8 Andreas Peter<sup>1,2,5</sup>, Andreas Fritsche<sup>1,2,3</sup>, Robert Wagner<sup>1,2,3</sup>

9  
10 1. Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center  
11 Munich at the University of Tübingen, Tübingen, Germany

12 2. German Center for Diabetes Research (DZD), Neuherberg, Germany

13 3. Department of Internal Medicine, Division of Endocrinology, Diabetology and  
14 Nephrology, Eberhard Karls University Tübingen, Tübingen, Germany

15 4. Institute for Clinical Chemistry and Pathobiochemistry, Department for Diagnostic  
16 Laboratory Medicine, University Hospital Tübingen, Tübingen, Germany.

17 5. German Institute of Human Nutrition, Potsdam-Rehbrücke, Germany

18

19

20 Corresponding author

21

22 Louise Fritsche, PhD

23 University Hospital Tübingen, Department of Internal Medicine IV

24 Otfried-Müller-Str. 10

25 72076 Tübingen

26 Germany

27 E-mail: [louise.fritsche@med.uni-tuebingen.de](mailto:louise.fritsche@med.uni-tuebingen.de)

28 Phone: +49 7071 2980687

29

30 Word count: 1482

31 Number of figures: 1

32 Number of tables: 2

33 Number of supplementary figures: 3

34

35

36

37

38

39

40

41

42

43

44

45

46 **Abbreviations**

47	AUC	Area under the curve
48	DPP-4	Dipeptidyl Peptidase IV
49	GDM	Gestational diabetes mellitus
50	GIP	Glucose dependent insulinotropic peptide
51	GLP-1	Glucagon like peptide-1
52	GLP-1R	Glucagon like peptide-1 receptor
53	IGI	Insulinogenic index
54	NEFA-ISI	Nonesterified fatty acids - Insulin sensitivity index
55	NGT	Normal glucose tolerance
56	OGTT	Oral glucose tolerance test

## 57 Abstract

58

### 59 Background

60 Incretins are crucial stimulators of insulin secretion after food intake. We investigated  
61 the incretin response during an oral glucose tolerance test in pregnant women with  
62 and without gestational diabetes.

### 63 Methods

64 Subjects underwent a 5-point OGTT with 75 g glucose. We assessed insulin  
65 secretion and levels of total GLP-1, GIP, glicentin and glucagon during the OGTT.

### 66 Findings

67 We examined 167 women (33 with GDM) during gestational week  $26.95 \pm 2.15$ .  
68 Insulin secretion was significantly lower in women with GDM ( $p < 0.001$ ). Postprandial  
69 GLP-1 and GIP were ~20% higher in women with GDM (all  $p < 0.05$ ) independent  
70 from age, BMI and gestational age. GLP-1 increase associated with insulin secretion  
71 only in GDM, but not in NGT. Postprandial GLP-1 levels associated negatively with  
72 birth weight.

### 73 Interpretation

74 The more pronounced GLP-1 increase in women with GDM could be part of a  
75 compensatory mechanism counteracting GLP-1 resistance. Higher GLP-1 levels  
76 might be protective against fetal overgrowth.

### 77 Funding

78 This study was supported in part by a grant from the Federal Ministry of Education  
79 and Research (BMBF) (01GI0925) to the German Center for Diabetes Research  
80 (DZD).

81 **Keywords**

82 GDM, Incretins, GLP-1, birth weight

## 83 Introduction

84

85 Gestational diabetes mellitus (GDM) affects 13% of pregnancies with increasing  
86 incidence. In pregnancy, insulin resistance develops during the 2<sup>nd</sup> trimester and is  
87 normally compensated by an increase in insulin secretion <sup>1</sup>. However, if this  
88 compensatory increase in insulin secretion falls short, glucose levels rise and GDM  
89 develops. When insulin resistance is resolved after delivery, glucose rapidly  
90 normalizes. Nevertheless, women who had GDM are at risk to subsequently develop  
91 type 2 diabetes <sup>2</sup>.

92 After food intake, specialized cells in the gastrointestinal tract release incretin  
93 hormones. The best studied incretins are glucagon like peptide 1 (GLP-1) and  
94 glucose-dependent insulintropic peptide (GIP). GLP-1 is cleaved from its precursor  
95 proglucagon along with other peptides, including glicentin and oxyntomodulin.  
96 Proglucagon gene products in pancreatic  $\alpha$ -cells give rise to glucagon.

97 GLP-1 and GIP are strong enhancers of glucose-stimulated insulin secretion. This  
98 incretin effect is reduced in type 2 diabetes and GDM <sup>3</sup>.

99 However, only a few studies investigated GLP-1 and GIP concentrations in GDM and  
100 reported contrasting results <sup>4-7</sup>. One study investigated glucagon and detected higher  
101 fasting and post-glucose-challenge concentrations in GDM <sup>8</sup>. No studies on glicentin  
102 in pregnancy have been published so far.

## 103 Objective

104 The aim of our study was to investigate the response of incretins and glucagon  
105 during an oral glucose tolerance test in pregnancy in a large cohort of well  
106 phenotyped women with normal glucose tolerance and GDM using precise pre-  
107 analytics and specific immunoassays.

## 108 Methods

109

### 110 Subjects

111 We analyzed data from an ongoing study aiming to characterize metabolic alterations  
112 during pregnancy (PREG), a cohort study recruiting women undergoing oral glucose  
113 tolerance tests for screening of GDM (NCT04270578). Pregnant women were  
114 examined between gestational week 24+0 and 31+6 with a 2h-OGTT with 75 g  
115 glucose. GDM was diagnosed using the IADPSG criteria <sup>9</sup> and patients were  
116 subsequently treated according to national guidelines, which was not part of the  
117 study. The detailed study protocol has been described elsewhere <sup>10</sup>. Informed written  
118 consent was obtained from every study participant. The study protocol has been  
119 approved by the local ethics boards and the study is conducted in accordance with  
120 the declaration of Helsinki. Patients were not involved in the design of the study.  
121 Meetings to connect study participants and researchers are held annually.

122

### 123 OGTT, laboratory analyses and anthropometric assessment

124 After an overnight fasting period of 12h, all study participants underwent 5-point  
125 OGTT with 75 g of glucose. Venous blood was collected at fasting and after 30, 60,  
126 90 and 120 minutes. Plasma glucose and nonesterified fatty acids were measured  
127 from sodium-fluoride plasma in an ADVIA chemistry XPT autoanalyzer (Siemens  
128 Healthcare Diagnostics) at all timepoints. Serum insulin and C-peptide were analyzed  
129 using ADVIA Centaur XPT immunoassay system (Siemens AG) at all timepoints. For  
130 the measurement of total GIP, total GLP-1, glicentin and glucagon EDTA-plasma  
131 from timepoint 0, 30 and 120 minutes was stabilized with 300 ng/mL of the protease  
132 inhibitor aprotinin (Sigma, Merck, Germany) und subsequently processed at 4°C and

133 kept frozen at -80°C until batch measurement. Incretins and glucagon were  
134 measured with commercially available ELISA assays (Merckodia, Sweden) according  
135 to the manufacturer's instructions. Height and weight were measured at the day of  
136 OGTT. Pregestational weight, parity, gestational age at birth and birthweight were  
137 obtained from maternal medical logs. Birth outcome data were available from 135  
138 participants. Insulin sensitivity was calculated using the NEFA-ISI index <sup>11</sup>. Insulin  
139 secretion was assessed with  $\frac{AUC_{C-peptide\ 0-30}}{AUC_{Glucose\ 0-30}}$  and with  $\Delta C-peptide_{0-30}$ .

140

#### 141 [Statistical analysis](#)

142 All statistical analyses were performed with R Version 3.6.1. In linear regression  
143 models skewed variables were log-transformed to approximate normal distribution.  
144 Group differences were tested with t-tests for normal distributed variables, Kruskal-  
145 Wallis-test for non-normal distributed variables and Chi<sup>2</sup>-test for categorical variables.  
146 The provided  $\beta$  coefficients are standardized estimates of the linear regression model  
147 terms. A p-value <0.05 was considered statistically significant.

148

## 149 [Results](#)

150 We analyzed data from 167 women, in 33 GDM was diagnosed. Patients with GDM  
151 were older, more likely to be multiparous, but BMI was not different from women with  
152 normal glucose tolerance (NGT; Table 1).

153

#### 154 [Glucose and hormones during OGTT](#)

155 Insulin secretion and sensitivity were lower in GDM (Figure 1 A, B). Areas under the  
156 curve (AUCs) of glucose and C-peptide were higher in GDM (Figure 1 C, D). While



157 fasting levels of GLP-1 and GIP were similar, the levels at 30min were higher in GDM  
158 (Table 2). The AUCs of GLP-1 and GIP were also higher in GDM (all  $p < 0.05$ , Figure  
159 1 E, F, Table 2). Fasting glicentin, glucagon, and their post-load kinetics were not  
160 different between groups ( $p \geq 0.1$ , Figure 1 G, H, Table 2).

161

#### 162 [GLP-1 associates with insulin secretion only in women with GDM](#)

163 We hypothesized that higher incretin levels in GDM represent a compensatory effect  
164 to boost insulin secretion. Therefore, we analyzed the associations of GLP-1 and  
165 glucose with insulin secretion (Figure S1). In NGT, increase in glucose between 0-  
166 30min associated with insulin secretion (Figure S1 A,  $p < 0.0001$ ). No such association  
167 was present for GLP-1 (panel B,  $p = 0.43$ ).

168 In contrast, women with GDM showed no association of glucose (Figure S1 C,  $p = 0.6$ )  
169 but a positive association of GLP-1 with insulin secretion (panel D,  $p = 0.0004$ ). This  
170 remained significant after adjustment for glucose change and basal insulin. Glicentin  
171 was similarly associated with insulin secretion in GDM and NGT (Figure S2). For GIP  
172 there was no association with insulin secretion (Figure S3).

173

#### 174 [Higher GLP-1 associates with lower birth weight](#)

175 Birth weight negatively associated with AUC GLP-1 ( $p = 0.0182$ ,  $\beta = -76.94$ ), 30min  
176 GLP-1 ( $p = 0.0248$ ,  $\beta = -72.6$ ) and trend for negative association with 30min GIP  
177 ( $p = 0.0814$ ,  $\beta = -57.45$ , all models adjusted for gestational age at birth, fetal sex and  
178 pregestational BMI). Since GLP-1 and GIP concentrations were higher in GDM, the  
179 models were additionally adjusted for GDM. Associations of birth weight with AUC  
180 GLP-1 and 30min GLP-1 remained significant ( $p = 0.0296$ ,  $\beta = -72.43$  and  $p = 0.0381$ ,  
181  $\beta = -68.49$ , respectively).

182

## 183 Discussion

### 184 Main findings

185 In this study, we find significantly higher postprandial GLP-1 and GIP levels in  
186 pregnant women with gestational diabetes compared to women with normal glucose  
187 tolerance, independent from age, body mass index and gestational age. The  
188 postprandial GLP-1 increase associated with insulin secretion in women with GDM  
189 but not in women with NGT, where insulin secretion was glucose driven. Offspring of  
190 women with higher GLP-1 levels also had lower birth weights.

### 191 Interpretation

192 GLP-1 and GIP have previously been investigated in women with and without GDM  
193 in smaller studies with different results <sup>4,6,7,12</sup>. One study used a different stimulus  
194 (mixed meal test) <sup>6</sup> and large BMI differences <sup>6,12</sup> between NGT and GDM subjects  
195 might further confound analyses, because BMI negatively associates with GLP-1 and  
196 GIP <sup>13</sup>. Similar BMI between groups allowed analyzing impact of GDM on incretin  
197 responses, without adiposity as confounder.

198 Intestinal L-cells also secrete glicentin, a potential biomarker of L-cell secretion <sup>14</sup>.  
199 Lack of difference in glicentin between NGT and GDM argues against an unselective  
200 L-cell hypersecretion in GDM.

201 In contrast to findings on glucagon outside of pregnancy <sup>15</sup>, we and others <sup>6</sup> did not  
202 detect links to diabetes. This argues against a major contribution of glucagon in the  
203 pathogenesis of GDM, while it might have some value in the prognosis of subsequent  
204 insulin requirement for the treatment of GDM <sup>16</sup>.

205 Of note, women with GDM had lower insulin secretion despite higher GLP-1  
206 concentrations. Our correlational analyses indicate an important contribution of GLP-  
207 1 to insulin secretion, especially in GDM. However, this GLP-1 stimulus is still not

208 sufficient to control hyperglycemia. The failure of adequate insulin secretion despite  
209 elevated GLP-1 indicates incretin resistance in GDM. The more pronounced GLP-1  
210 response in GDM could be counteracting incretin resistance.

211 One potential contributor to incretin resistance is genetic background.  
212 Polymorphisms in *TCF7L2* associate with elevated GDM risk<sup>17</sup> and reduced GLP-1-  
213 stimulated insulin secretion<sup>18</sup>. Another possible contributor might be dipeptidyl  
214 peptidase IV (DPP-4) activity, the enzyme degrading GLP-1 and GIP. Liu et al.<sup>19</sup>  
215 reported no differences of DPP-4 in maternal serum and the unaltered fasting GLP-1  
216 levels in GDM in our study argue against largely different DPP-4 activity.  
217 Furthermore, insulin resistance and hyperglycemia which are present in GDM are  
218 associated with incretin resistance<sup>18</sup>.

219 In our study neonates of women with higher GLP-1 levels during pregnancy had  
220 lower birth weight, independent of glycemia. This points towards a protection of GLP-  
221 1 against excessive fetal growth. Our findings are in line with a report of negative  
222 association between fasting maternal GLP-1 and fetal abdominal circumference and  
223 birth weight<sup>20</sup>. Higher GLP-1, also via decelerated gastric emptying, might reduce  
224 postprandial glucose which is associated with fetal overgrowth. If this hypothesis  
225 holds true, GLP-1 receptor agonists or DPP-4 inhibitors might have benefits in GDM.  
226 To our knowledge, currently no studies test GLP-1R agonists in GDM. One trial  
227 reported higher insulin secretion after 16 weeks treatment with the DPP-4 inhibitor  
228 sitagliptin in GDM<sup>21</sup>. However, neither incretins nor birth outcomes were reported.

## 229 **Strengths and limitations**

230 The strength of our study is the large number of subjects of our extensively  
231 phenotyped cohort of pregnant women. The sample preparation and measurement of  
232 incretins was done according to standard operating procedures and with state-of-the-

233 art measuring method. One weakness is the relatively low number of patients with  
234 GDM.

235

## 236 Conclusion

237 In summary, elevated GLP-1 could be part of a compensatory attempt to counteract  
238 GLP-1 resistance in GDM. Higher GLP-1 levels might protect against fetal  
239 overgrowth. Our data suggest that not only glucose-stimulated but also incretin-  
240 stimulated insulin secretion contributes to GDM. Further studies are needed to  
241 translate these findings into improved therapeutic strategies to prevent or treat GDM  
242 and circumvent unfavorable impact on the developing child.

## 243 Acknowledgement

244 We thank all of the volunteers for their participation in the study. We especially thank  
245 Ines Wagener, Eva-Maria Stehle, Alexandra Eberle, Dorothee Neuscheler, Henrike  
246 Peuker, Elisabeth Metzinger and Heike Runge for their excellent technical  
247 assistance.

248

## 249 Disclosure of interests

250 RW reports lecture fees from NovoNordisk and travel grants from Eli Lilly. He served  
251 on the advisory board of Akcea Therapeutics. In addition to his current work, ALB  
252 reports lecture fees from Astra Zeneca, Boehringer Ingelheim, and NovoNordisk. He  
253 served on advisory boards of Astra Zeneca, Boehringer Ingelheim and NovoNordisk.  
254 Besides his current work, AF reports lecture fees and advisory board membership  
255 from Sanofi, Novo Nordisk, Eli Lilly, and AstraZeneca. In addition to is current work,

256 MH reports research grants from Boehringer Ingelheim and Sanofi (both to the  
257 University Hospital of Tuebingen) and lecture fees from Sanofi, Novo Nordisk, Eli Lilly  
258 and Merck Sharp Dohme. None of the other authors report a conflict of interest  
259 directly related to the content of this work.  
260

## 261 Contribution of authorship

262 LF researched and analyzed data and drafted the manuscript. JH, SN, and RW  
263 researched data. HUH, ALB, HP, AS, and AF contributed to the discussion and  
264 interpretation of the results. AP supervised the laboratory measurements and  
265 interpreted results. RW and MH supervised the project. All authors contributed to  
266 discussion and approved the final manuscript prior to submission. RW is the  
267 guarantor of this work and, as such, had full access to all the data in the study and  
268 takes responsibility for the integrity of the data and the accuracy of the data analysis.  
269

## 270 Details of Ethics Approval

271 The study protocol has been approved by the ethics board of the University of  
272 Tuebingen (No. 218/2012BO2, 06/15/2012).  
273

## 274 Funding

275 This study was supported in part by a grant from the Federal Ministry of Education  
276 and Research (BMBF) (01GI0925) to the German Center for Diabetes Research  
277 (DZD).  
278

## 279 Registration

280 The PREG Study is registered with clinicaltrials.gov NCT 04270578.

281

## 282 Data availability

283 All requests for data and materials will be promptly reviewed by the Data Access  
284 Steering Committee to verify whether the request is subject to any intellectual  
285 property or confidentiality obligations. Individual-level data may be subject to  
286 confidentiality. Any data and materials that can be shared will be released via a  
287 Material Transfer Agreement.

288

289

## 290 References

291

292 1. Powe CE, Huston Presley LP, Locascio JJ, Catalano PM. Augmented insulin  
293 secretory response in early pregnancy. *Diabetologia*. 2019 Aug 1;62(8):1445–  
294 52.

295 2. Kim C, Newton KM, Knopp RH. Gestational Diabetes and the Incidence of Type  
296 2 Diabetes. *Diabetes Care*. 2002 Oct 1;25(10):1862–8.

297 3. Kosinski M, Knop FK, Vedtofte L, Grycewicz J, Swierzewska P, Cypryk K, et al.  
298 Postpartum reversibility of impaired incretin effect in gestational diabetes  
299 mellitus. *Regulatory Peptides*. 2013 Sep 10;186:104–7.

- 300 4. Cypryk K, Vilsbøll T, Nadel I, Smyczyńska J, Holst JJ, Lewiński A. Normal  
301 secretion of the incretin hormones glucose-dependent insulinotropic polypeptide  
302 and glucagon-like peptide-1 during gestational diabetes mellitus. *Gynecological*  
303 *Endocrinology*. 2007 Jan 1;23(1):58–62.
- 304 5. Mosavat M, Omar SZ, Jamalpour S, Tan PC. Serum Glucose-Dependent  
305 Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) in  
306 association with the Risk of Gestational Diabetes: A Prospective Case-Control  
307 Study. Adamska-Patruno E, editor. *Journal of Diabetes Research*. 2020 Jan  
308 29;2020:9072492.
- 309 6. Bonde L, Vilsbøll T, Nielsen T, Bagger JI, Svare JA, Holst JJ, et al. Reduced  
310 postprandial GLP-1 responses in women with gestational diabetes mellitus.  
311 *Diabetes, Obesity and Metabolism*. 2013;15(8):713–20.
- 312 7. Lencioni C, Resi V, Romero F, Lupi R, Volpe L, Bertolotto A, et al. Glucagon-like  
313 peptide-1 secretion in women with gestational diabetes mellitus during and after  
314 pregnancy. *J Endocrinol Invest*. 2011 Oct;34(9):e287-290.
- 315 8. Beis C, Grigorakis SI, Philippou G, Alevizaki M, Anastasiou E. Lack of  
316 suppression of plasma glucagon levels in late pregnancy persists postpartum  
317 only in women with previous gestational diabetes mellitus. *Acta Diabetol*. 2005  
318 Mar;42(1):31–5.
- 319 9. International Association of Diabetes and Pregnancy Study Groups Consensus  
320 Panel, Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, et al.  
321 International association of diabetes and pregnancy study groups

- 322 recommendations on the diagnosis and classification of hyperglycemia in  
323 pregnancy. *Diabetes Care*. 2010 Mar;33(3):676–82.
- 324 10. Fritsche L, Hummel J, Wagner R, Loeffler D, Hartkopf J, Machann J, et al. The  
325 German Gestational Diabetes Study (PREG): Rationale, Methodology and  
326 Design [Internet]. 2021 [cited 2021 Oct 12]. p. 2021.10.10.21264499. Available  
327 from: <https://www.medrxiv.org/content/10.1101/2021.10.10.21264499v1>
- 328 11. Wagner R, Fritsche L, Heni M, Fehlert E, Stefan N, Staiger H, et al. A novel  
329 insulin sensitivity index particularly suitable to measure insulin sensitivity during  
330 gestation. *Acta Diabetol*. 2016 Dec;53(6):1037–44.
- 331 12. Sukumar N, Bagias C, Goljan I, Weldeselassie Y, Gharanei S, Tan BK, et al.  
332 Reduced GLP-1 Secretion at 30 Minutes After a 75-g Oral Glucose Load Is  
333 Observed in Gestational Diabetes Mellitus: A Prospective Cohort Study.  
334 *Diabetes*. 2018 Dec 1;67(12):2650–6.
- 335 13. Færch K, Torekov SS, Vistisen D, Johansen NB, Witte DR, Jonsson A, et al.  
336 GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected  
337 Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO  
338 Study. *Diabetes*. 2015 Jul;64(7):2513–25.
- 339 14. Perakakis N, Mantzoros CS. The Role of Glicentin and Oxyntomodulin in Human  
340 Metabolism: New Evidence and New Directions. *J Clin Endocrinol Metab*. 2020  
341 Aug 1;105(8):e3003–5.
- 342 15. Wagner R, Hakaste LH, Ahlqvist E, Heni M, Machann J, Schick F, et al.  
343 Nonsuppressed Glucagon After Glucose Challenge as a Potential Predictor for  
344 Glucose Tolerance. *Diabetes*. 2017 May 1;66(5):1373–9.



- 345 16. Horie I, Haraguchi A, Ito A, Nozaki A, Natsuda S, Akazawa S, et al. Impaired  
346 early-phase suppression of glucagon secretion after glucose load is associated  
347 with insulin requirement during pregnancy in gestational diabetes. *J Diabetes*  
348 *Investig.* 2020 Jan;11(1):232–40.
- 349 17. Fritsche L, Sarief M, Wagner R, Stefan N, Lehmann R, Häring H-U, et al.  
350 Genetic variation in TCF7L2 rs7903146 and history of GDM negatively and  
351 independently impact on diabetes-associated metabolic traits. *Diabetes Res Clin*  
352 *Pract.* 2018 Dec;146:251–7.
- 353 18. Herzberg-Schäfer S, Heni M, Stefan N, Häring H-U, Fritsche A. Impairment of  
354 GLP1-induced insulin secretion: role of genetic background, insulin resistance  
355 and hyperglycaemia. *Diabetes, Obesity and Metabolism.* 2012;14(s3):85–90.
- 356 19. Liu B, Deng S, Xu Y, Yang J, Geng H, Wang Z. Association between maternal  
357 and umbilical cord serum dipeptidyl peptidase IV in pregnant women with and  
358 without gestational diabetes mellitus. *Journal of Obstetrics and Gynaecology*  
359 *Research.* 2016;42(5):505–10.
- 360 20. Valsamakis G, Margeli A, Vitoratos N, Boutsiadis A, Sakkas EG, Papadimitriou  
361 G, et al. The role of maternal gut hormones in normal pregnancy: fasting plasma  
362 active glucagon-like peptide 1 level is a negative predictor of fetal abdomen  
363 circumference and maternal weight change. *European Journal of Endocrinology.*  
364 2010 May 1;162(5):897–903.
- 365 21. Sun X, Zhang Z, Ning H, Sun H, Ji X. Sitagliptin down-regulates retinol-binding  
366 protein 4 and reduces insulin resistance in gestational diabetes mellitus: a  
367 randomized and double-blind trial. *Metab Brain Dis.* 2017 Jun 1;32(3):773–8.

368

369

370 **Figure legend**

371

372 **Figure 1** Insulin secretion (A) and insulin sensitivity (B) in women with and without GDM and time course of  
373 glucose (C), C-peptide (D), GLP-1 (E), GIP (F), glicentin (G) and glucagon (H) during OGTT. Data are  
374 presented as mean  $\pm$  standard error. Blue represent NGT, red GDM. Group differences between GDM and NGT  
375 for AUCs of glucose, insulin and C-peptide were tested with Kruskal-Wallis-test. Differences between groups  
376 for insulin sensitivity, incretins and glucagon were tested with multivariate linear regression adjusted for age,  
377 BMI and gestational week and for insulin secretion additionally adjusted for insulin sensitivity.

378

379 **Tables**

380 **Table 1 Subject characteristics of the pregnant cohort and birth outcome parameters**

<b>Characteristics</b>	<b>NGT (n = 134)</b>	<b>GDM (n = 33)</b>	<b>p</b>	<b>p adjusted</b>
<b>Age</b>	32.71 (4.31)	35.03 (3.84)	0.005*	-
<b>BMI (kg/m<sup>2</sup>)</b>	26.90 [23.97, 29.94]	26.90 [24.72, 30.99]	0.497	-
<b>Pregestational BMI (kg/m<sup>2</sup>)</b>	25.37 (5.25)	25.50 (4.96)	0.906	-
<b>Gestational weight gain (kg)</b>	14.06 (5.53)	11.46 (7.10)	0.085	-
<b>Parity (%)</b> Nulliparous Multiparous	69 (51.5) 65 (48.5)	9 (27.37) 24 (72.7)	0.021*	-
<b>Gestational age at OGTT (weeks)</b>	26.87 (2.16)	27.27 (2.11)	0.332	-
<b>Fasting glucose (mmol/L)</b>	4.28 [4.07, 4.54]	4.56 [4.33, 4.94]	<0.001*	-
<b>1 h glucose (mmol/L)</b>	7.70 [6.40, 8.56]	10.61 [9.56, 11.33]	<0.001*	-
<b>2 h glucose (mmol/L)</b>	6.11 [5.34, 6.83]	8.83 [7.72, 9.44]	<0.001*	-
<b>Fasting insulin (pmol/L)</b>	59 [42, 79]	69[41, 84]	0.460	-
<b>Fasting C-peptide (pmol/L)</b>	381.50 [296.50, 496.50]	466.00 [282.00, 652.00]	0.150	-
<b>Insulin sensitivity (NEFA-ISI)</b>	3.34 [2.56, 4.39]	2.72 [2.01, 4.26]	0.031*	0.003*†
<b>Insulin secretion (AUC<sub>C-pep 0-30</sub>/AUC<sub>Glucose0-30</sub>)</b>	179.22 (60.12)	155.17 (54.53)	0.037*	<0.001*‡
<b>Birth weight (g) #</b>	3478.18 (479.84)	3321.52 (384.38)	0.084	0.24 §
<b>Birth length (cm) #</b>	51.48 (2.37)	50.48 (2.68)	0.042	0.27 §
<b>Gestational age at birth (weeks)<sup>4</sup></b>	39.51 (1.59)	39.16 (1.17)	0.240	-

381 Data are presented as means (SD), median [IQR] and numbers (%). Group  
 382 differences were tested with T-test for normal distributed variables, Kruskal-Wallis-  
 383 test for nonnormal distributed variables and Chi2-test for categorical variables.  
 384 \*indicates statistical significance. † Adjusted for age, BMI and gestational age, ‡  
 385 adjusted for age, BMI, gestational age and insulin sensitivity, § adjusted for  
 386 gestational age and fetal sex, # n=135. NGT = normal glucose tolerance.  
 387









388 Table 2 Incretin concentrations during OGTT and AUCs in the pregnant cohort

Incretin	NGT (n = 134)	GDM (n = 33)	p	p adjusted †
<b>GLP-1 min 0</b> (pmol/L)	4.48 [3.42, 5.53]	4.83 [3.56, 6.18]	0.393	0.6
<b>GLP-1 min 30</b> (pmol/L)	9.89 [7.10, 12.83]	11.31 [8.65, 14.98]	0.034*	0.03*
<b>GLP-1 min 120</b> (pmol/L)	5.71 [4.55, 8.27]	6.48 [5.05, 9.30]	0.175	0.3
<b>AUC GLP-1</b> (min-pmol/L)	911.19 [726.59, 1207.49]	1136.24 [913.21, 1342.74]	0.03*	0.03*
<b>GIP min 0</b> (pmol/L)	0.81 [0.81, 1.50]	0.81 [0.81, 1.76]	0.312	0.5
<b>GIP min 30</b> (pmol/L)	20.21 [14.12, 29.69]	24.12 [18.76, 35.77]	0.049*	0.02*
<b>GIP min 120</b> (pmol/L)	17.48 [11.92, 23.58]	19.20 [14.96, 27.13]	0.191	0.1
<b>AUC GIP</b> (min-pmol/L)	2022.49 [1421.28, 2887.34]	2532.15 [1899.17, 3219.01]	0.045*	0.04*
<b>Glicentin min 0</b> (pmol/L)	12.37 [8.53, 16.92]	12.59 [9.56, 16.56]	0.989	0.9
<b>Glicentin min</b> <b>30 (pmol/L)</b>	25.10 [19.26, 34.73]	28.33 [25.16, 35.13]	0.122	0.1
<b>Glicentin min</b> <b>120 (pmol/L)</b>	20.17 [14.97, 30.45]	21.66 [14.44, 29.84]	0.602	0.3
<b>AUC Glicentin</b> (min-pmol/L)	2715.75 [2092.97, 3529.69]	2912.80 [2426.76, 3574.03]	0.198	0.1
<b>Glucagon min</b> <b>0 (pmol/L)</b>	1.45 [0.81, 3.42]	1.43 [0.95, 2.96]	0.873	0.6

<b>Glucagon min 30 (pmol/L)</b>	1.35 [0.55, 2.20]	1.15 [0.78, 2.54]	0.550	0.4
<b>Glucagon min 120 (pmol/L)</b>	0.91 [0.44, 1.53]	0.74 [0.46, 1.50]	1.000	0.9
<b>AUC Glucagon (min·pmol/L)</b>	139.11 [74.68, 236.32]	124.74 [89.05, 262.70]	0.659	0.9

389 Data are presented as median [IQR]. Simple group differences were tested with  
390 Kruskal-Wallis-test. † adjusted for age, BMI and gestational week. \*indicates  
391 statistical significance.

Fig.1



NGT GDM